Comparable stake leader
Commodore Capital LP
SEC ownership of Perspective Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000728387.
Disclosed value leader
TCG Crossover Management, LLC
Comparable rows
50/50
Latest evidence
23 Jun 2026
- Public ticker
- CATX on NYSE
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Commodore Capital LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Commodore Capital LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
23 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000728387
- Issuer location
- Seattle, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Perspective Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Commodore Capital LP
Disclosed value leader
TCG Crossover Management,...
Comparable rows
50/50
Latest evidence
23 Jun 2026
13D/G
13F
Lead comparable stake: 9.9%
13D/G row: Commodore Capital LP
Showing 1-8 of 50 holder rows.
Quick read
Commodore Capital LP leads the comparable SEC ownership view at 9.9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Commodore Capital LP's linked filing trail.
Comparable ownership
Top 5
Commodore Capital LP
9.9%
TCG Crossover GP II, LLC
6.9%
Qatar Investment Authority
6.2%
Avidity Partners Management LP
5.3%
BlackRock, Inc.
4.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Commodore Capital LP |
13D/G
13F
Company
|
9.9%
|
$29,968,780
11,939,753 shares
|
$0 | 02 Feb 2026 |
| TCG Crossover GP II, LLC |
13D/G
Chen Yu
|
6.9%
|
$21,767,809
7,915,567 shares
|
$0 | 03 Feb 2026 |
| Qatar Investment Authority |
13D/G
|
6.2%
|
$19,451,597
7,073,308 shares
|
$0 | 04 Feb 2026 |
| Avidity Partners Management LP |
13D/G
13F
Company
|
5.3%
|
$29,523,995
6,049,999 shares
|
+$15,659,798 | 20 Feb 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
4.6%
from 13D/G
|
$22,303,498
5,348,561 shares
|
— | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
4.3%
|
$17,764,795
4,893,883 shares
|
$0 | 23 Jun 2026 |
| MORGAN STANLEY |
13D/G
13F
Company
|
2.6%
|
$13,080,088
2,959,296 shares
|
-$6,641,479 | 31 Mar 2026 |
| FMR LLC |
13F
13D/G
Company
|
0.4%
from 13D/G
|
$1,307,954
313,658 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$42,241.
Buys
$42,241
Insiders: 2
Sells
$0
Insiders: 0
Net
+$42,241
Shares: +20,498
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 20,498
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 20,498 | 0 | $42,241 | $0 | +$42,241 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Perspective Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Lantheus Alpha Therapy, LLC
Net 12M change
+$42,241
Latest report
02 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 10%+ Owner | $110,934,724 | Filing P/S | 06 Mar 2024 | ||
| Lori A. Woods | Director | $400,989 | Mixed | 02 Mar 2026 | ||
| Robert F. Williamson III | Director | $394,522 | +$19,946 | +5.3% | Mixed | 02 Mar 2026 |
| Johan M. Spoor | Chief Executive Officer, Director | $194,133 | Mixed | 02 Mar 2026 | ||
| Jonathan Robert Hunt | Chief Accounting Officer | $121,202 | +$22,295 | +23% | Filing P/S | 02 Mar 2026 |
| Juan Graham | Chief Financial Officer | $79,490 | Filing P/S | 28 Mar 2025 | ||
| Mark John Austin | VP Finance/Prin Fin&Acct Offic | $30,251 | Mixed | 17 Jul 2024 | ||
| Philip J. Vitale | Director | Mixed | 21 Jul 2022 | |||
| Alan Hoffmann | Director | Mixed | 21 Jul 2022 | |||
| William Cavanagh | Chief R&D Officer | Mixed | 21 Jul 2022 | |||
| Frank Morich | Director | Mixed | 02 Mar 2026 | |||
| Michael W. McCormick | Director | Mixed | 21 Feb 2023 | |||
| Jennifer Streeter | COO & VP of HR | Mixed | 12 Jun 2023 | |||
| Markus Puhlmann | Chief Medical Officer | Mixed | 02 Mar 2026 | |||
| Maria E. Martinez | Director | Mixed | 02 Mar 2026 | |||
| Joel Sendek | Chief Financial Officer | Mixed | 04 Sep 2025 | |||
| Heidi Henson | Director | Mixed | 02 Mar 2026 |
Recent insider transactions for Perspective Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Maria E. Martinez | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Frank Morich | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Robert F. Williamson III | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Heidi Henson | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Lori A. Woods | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Johan M. Spoor | CATX | Stock option (right to buy) | Award | 735,000 | 735,000 | 02 Mar 2026 | Direct | |||
| Jonathan Robert Hunt | CATX | Stock option (right to buy) | Award | 90,000 | 90,000 | 02 Mar 2026 | Direct | |||
| Markus Puhlmann | CATX | Stock option (right to buy) | Award | 150,000 | 150,000 | 02 Mar 2026 | Direct | |||
| Jonathan Robert Hunt | CATX | Common Stock | Purchase | 22.5% | $22,295 | $2.03 | 11,000 | 59,800 | 13 Nov 2025 | Direct |
| Robert F. Williamson III | CATX | Common Stock | Purchase | 2595.1% | $19,946 | $2.10 | 9,498 | 9,864 | 12 Nov 2025 | RFW3 Revocable Trust |
| Joel Sendek | CATX | Stock option (right to buy) | Award | 600,000 | 600,000 | 04 Sep 2025 | Direct | |||
| Maria E. Martinez | CATX | Stock option (right to buy) | Award | 75,000 | 75,000 | 03 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.